Antibody-Drug Conjugate– tag –
-
Upstream Process Optimization Drives Biologics Production Efficiency Towards Continuous and Perfusion Systems
World Pharma Today Unknown Overview Optimizing upstream processes is critical for enhancing biologics production efficiency, with a strong focus on cell culture media design, feed strategies, and bioreactor control. Chemically defined, s... -
FDA Approves Multiple Novel Cancer Therapeutics, Including Multi-Selective RAS(ON) Inhibitor Daraxonrasib and Next-Gen ADCs for Difficult-to-Treat Cancers
The ASCO Post USA Overview The U.S. FDA announced several groundbreaking cancer drug approvals on September 10, 2026, including daraxonrasib, a multi-selective RAS(ON) inhibitor, for metastatic pancreatic adenocarcinoma. Other approvals ... -
OS Therapies Strengthens FDA & MHRA Alignment, Joins Project Orbis for OST-HER2 Metastatic Osteosarcoma Program
OS Therapies USA Overview OS Therapies announced strengthened alignment with the FDA and MHRA and approval to join Project Orbis for its lead candidate, OST-HER2 (a next-generation tunable ADC) program for metastatic osteosarcoma. Projec... -
WuXi XDC Out-Licenses WuXiTecan-2 Linker-Payload Technology to Ona Therapeutics to Accelerate ADC Development
PR Newswire China Overview WuXi XDC announced the out-licensing of its innovative WuXiTecan-2 linker-payload technology platform to Ona Therapeutics, a Spanish biotechnology company, to advance novel Antibody-Drug Conjugate (ADC) researc... -
Shilpa Biologicals Opens GMP Facility for ADC Manufacturing in India’s Pharmacit
Biospectrum Jobs India Overview Shilpa Biologicals has inaugurated a new GMP-compliant facility in Pharmacit, India, dedicated to the manufacturing of Antibody-Drug Conjugates (ADCs). This state-of-the-art facility will provide end-to-en... -
Akeso’s EGFR/TROP2 Bispecific ADC AK158D1 Cleared for Phase I Clinical Trial in Advanced Solid Tumors by China’s NMPA
PR Newswire China Overview Akeso Inc., a Chinese biopharmaceutical company, announced that its EGFR and TROP2 bispecific antibody-drug conjugate (ADC) candidate, AK158D1, has received clearance from China's National Medical Products Admi... -
BioNTech Announces gotistobart Phase III Achieves Median OS of 18.5 Months in Squamous NSCLC at WCLC 2026
european biotechnology Germany Overview At the World Conference on Lung Cancer (WCLC) 2026 in Seoul, BioNTech presented pivotal data from the Phase III PRESERVE-003 trial for gotistobart (BNT316/ONC-392), a pH-sensitive anti-CTLA-4 antib... -
Novel Bispecific ADC ICP-B381, Targeting PSMA and STEAP1, Approved for Phase 1 Clinical Trials in China for Prostate Cancer; US IND Submission Underway
Prostate Warriors China Overview ICP-B381, a novel bispecific antibody-drug conjugate (ADC) designed to simultaneously target PSMA and STEAP1, has received approval from Chinese regulatory authorities to commence Phase 1 clinical trials ... -
Continuous Multi-Column Chromatography Integrates and Intensifies Monoclonal Antibody Downstream Processing, Boosting Efficiency and Sustainability
BioProcess International USA Overview The integration of two chromatography steps using a continuous multi-column chromatography (MCC) system is shown to dramatically improve the efficiency and sustainability of downstream processing in ... -
US Trade Policy and BIOSECURE Act Drive Major Reshaping and Investment in Global ADC Manufacturing Landscape
Bioprocess Online USA Overview U.S. trade policy and the BIOSECURE Act are significantly reshaping the Antibody-Drug Conjugate (ADC) manufacturing landscape, spurring substantial investments in capacity across the U.S., Europe, and Asia....
